Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18220314 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL1457085 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA9 | |
| SCHEMBL27181489 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA9 | |
| SCHEMBL10594377 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA9 | |
| SCHEMBL20715361 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2CA1CA9 | |
| SCHEMBL11462520 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL20715352 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL9813681 | 0.68 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL13219285 | 0.68 | CA1 (0.38) | CA1F2R | |
| SCHEMBL12135426 | 0.68 | SMN1; SMN2 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173353-B2 | Sulfonium compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173353-B2 | Sulfonium compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100248135-A1 | SULFONIUM COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248135-A1 | SULFONIUM COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100248135-A1 | SULFONIUM COMPOUND | PFAS, F12, AFF1 | SMN1; SMN2 2326/4885CHRM2 1203/4885CHRM1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.